A phase I clinical trial of dual blockade of CTLA-4 (ipilimumab) plus VEGF (bevacizumab) showed increased tumor antigen recognition, tumor-associated endothelial activation, and infiltration of T cells in melanomas (168). The gene discussed is CTLA4; the disease is neoplasm.